Abstract
Natural and vaccine-induced immunity are critical for controlling the SARS-CoV-2 pandemic. However, the emergence of variants like B.1.1.7 (Alpha) raised concerns regarding potential immune evasion. In this longitudinal cohort study of 13,109 healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection against symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2 or Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection. Our results demonstrate that both natural infection (detectable anti-spike antibodies) and two-dose vaccination provide robust protection (≥85%) against infection, including the B.1.1.7 variant.
Introduction
In early 2021, the global pandemic response faced two significant challenges: the real-world validation of vaccine efficacy outside of clinical trials and the emergence of the B.1.1.7 (Alpha) variant. While initial trials for the Pfizer-BioNTech and Oxford-AstraZeneca vaccines showed high efficacy, their performance in high-exposure environments—such as hospital settings—and against emerging lineages remained to be fully characterized. This study sought to quantify the protection offered by vaccination (comparing one versus two doses) and natural immunity, specifically assessing resilience against the B.1.1.7 variant.
Methods
The researchers conducted a longitudinal cohort study of 13,109 healthcare workers at Oxford University Hospitals (OUH) between September 2020 and February 2021.
Participant Classification
HCWs were categorized into three primary groups based on their status at the start of the study:
- Unvaccinated/Seronegative: No prior infection and no vaccine doses.
- Unvaccinated/Seropositive: Evidence of natural immunity via detectable anti-spike antibodies.
- Vaccinated: Received either one or two doses of BNT162b2 or ChAdOx1 nCOV-19.
Testing and Surveillance
The study utilized a comprehensive testing regimen including voluntary asymptomatic screening (PCR every two weeks), symptomatic testing, and regular serological (antibody) testing. To identify the B.1.1.7 variant, the team monitored S-gene target failure (SGTF) in PCR assays as a proxy and confirmed lineages using Oxford Nanopore whole-genome sequencing (WGS).
Statistical Analysis
Poisson regression was used to calculate adjusted incidence rate ratios (aIRRs), accounting for variables such as age, sex, ethnicity, and occupational risk (e.g., working on a COVID-19 ward). The primary dataset was generated by the OUH staff testing program, with genomic data archived in the European Nucleotide Archive (accession PRJEB43319).
Results
The study population included 8,285 HCWs who received the Pfizer-BioNTech vaccine and 2,738 who received the Oxford-AstraZeneca vaccine.
Protection Against Symptomatic Infection
Compared to the unvaccinated seronegative group, both natural immunity and a two-dose vaccine regimen provided near-total protection. No HCW who received two vaccine doses experienced a symptomatic infection during the study period. Natural immunity (seropositivity) was associated with a 98% reduction in symptomatic infection (aIRR 0.02 [95%CI <0.01-0.18]). A single vaccine dose offered a 67% reduction (aIRR 0.33 [0.21-0.52]).
Protection Against Any PCR-Positive Result
When considering all PCR-positive results (including asymptomatic cases), two vaccine doses provided 90% protection (0.10 [0.02-0.38]), while natural immunity provided 85% protection (0.15 [0.08-0.26]). A single dose reduced the incidence of any PCR-positive result by 64% (0.36 [0.26-0.50]).
B.1.1.7 Variant and Viral Load
There was no evidence of reduced protection against the B.1.1.7 variant compared to other lineages. Furthermore, breakthrough infections in vaccinated or previously infected individuals were characterized by significantly lower viral loads (indicated by higher Ct values), suggesting a potential reduction in transmissibility even when infection occurred.
Discussion
The findings highlight a "parity of protection" between natural immunity and full vaccination. The observation that natural infection resulting in detectable antibodies provides protection comparable to two vaccine doses was a critical insight for understanding population-level immunity during the early stages of the vaccine rollout.
The data also underscored the importance of the second vaccine dose. While a single dose provided substantial protection against symptomatic disease, the significant increase in protection against any infection (including asymptomatic carriage) after the second dose suggests that the full schedule is vital for breaking chains of transmission.
Limitations
The study's cohort primarily consisted of healthy, working-age adults, which may limit the generalizability of the findings to elderly or pediatric populations. Additionally, because testing was voluntary, there is a possibility of testing bias; individuals who felt protected by vaccination or prior infection might have been less likely to seek testing. Finally, while the study confirmed protection against B.1.1.7, the emergence of subsequent variants requires ongoing surveillance to determine the long-term durability of this immunity.
Conclusion
Both natural infection and two-dose vaccination provide robust, high-level protection against SARS-CoV-2 infection. Crucially, this immunity remains effective against the B.1.1.7 variant. These findings support the continued prioritization of full vaccination schedules to control the spread of the virus and protect high-risk populations like healthcare workers.
Summary updated